Having trouble accessing articles? Reset your cache.

ICA-105665: Suspended Phase IIa enrollment

Icagen suspended further enrollment in a single-blind, placebo-controlled, dose-ranging, U.S. Phase IIa trial after reporting that 1 patient experienced

Read the full 191 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE